Vitória França dos Santos Pessoa

Ms. Vitória França dos Santos Pessoa

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RBRaissa Nogueira Brito
Raissa Nogueira Brito
Ana Izabel Passarella TeixeiraAna Izabel Passarella Teixeira
Ana Izabel Passarella Teixeira
CGCarolina Carvalho Gontijo
Carolina Carvalho Gontijo
RFRafael Da Silva Faria
Rafael Da Silva Faria
WRWalter Massa Ramalho
Walter Massa Ramalho
Wildo AraujoWildo Araujo
Wildo Araujo
Estimating seroprevalence and vaccination coverage against COVID-19 is crucial to the development of well-targeted public health policies at the local level. Here, we estimated seroprevalence and vaccination coverage in a lower-middle-class population in Brazil. We conducted an observational, cross-sectional, population-based survey from 24 September to 19 December 2021. CMIA tests were used to detect anti-SARS-CoV-2 IgG against the N-protein. The overall seroprevalence was 24.15% (177/733), and vaccination coverage was 91.40% (670/733); 72.09% (483/670) were fully vaccinated. Among vaccinated participants, seroprevalence was 24.77% (95% CI 21.50–28.04; 166/670), with a prevalence ratio (PR) of 1.03 (95% CI 0.98–1.08; p-value 0.131). Among participants who received an mRNA vaccine with S-based epitope (485), seroprevalence was 16.29% (95% CI 13.04–19.85; 79/485). Among unvaccinated participants, seroprevalence was 17.46% (95% CI 10.04–28.62; 11/63). Finally, in spite of the political climate and other possible causes for vaccine hesitancy, the positive Brazilian culture towards vaccination might have curbed hesitancy.

Verified
Journal Article
Open access
PDF file
MMMarina Dias Marques
Marina Dias Marques
AMAline Moraes
Aline Moraes
TSTatiana Shiroma
Tatiana Shiroma
Vitória França dos Santos PessoaVitória França dos Santos Pessoa
Vitória França dos Santos Pessoa
Antonio ErmogesAntonio Ermoges
Antonio Ermoges
MHMariana Hecht
Mariana Hecht
Chagas disease (CD) is endemic in Latin America, with its pathogenesis linked to Trypanosoma cruzi (Tc) persistence and autoimmune responses. This study investigates the role of LINE-1 (L1) activation in inflammation and loss of self-tolerance during Tc infection. In vitro assays evaluated the expression of genes involved in L1 regulation and interferon signaling under basal conditions and following L1 suppression via CRISPR/dCas9. In vivo analyses in a murine model included L1 and IFN expression profiling, autoantibody quantification, and histopathological assessments of liver, spleen, intestine, and heart. Tc infection induced L1 upregulation, correlating with an increased expression of its inhibitors, MOV-10 and APOBEC-3, suggesting host-driven regulatory mechanisms. L1 activation was also associated with the upregulation of DNA repair pathways (MMR and NHEJ) and RNA-sensing pathways (MDA-5 and RIG-I), leading to type I interferon responses. In the murine model, L1 expression was highest in the intestine and heart, independent of parasite burden, and correlated with increased interferon gene expression and autoantibody production. Our findings suggest that CD pathogenesis involves L1-induced chronic inflammation, which may contribute to late-stage symptoms. This highlights self-recognition mechanisms in disease severity and reveals potential therapeutic targets for novel treatments.

5 March 2026 in Proceedings
Verified
Conference Paper
Open access
PDF file
Vitória França dos Santos PessoaVitória França dos Santos Pessoa
Vitória França dos Santos Pessoa
ECEduarda P. Correa
Eduarda P. Correa
MMMarcelo P. Machado
Marcelo P. Machado
Emãnuella Melgaço GarcezEmãnuella Melgaço Garcez
Emãnuella Melgaço Garcez
ACAmandda Carvalho
Amandda Carvalho
LHLuciana Hagstrom Hagström
Luciana Hagstrom Hagström
Introduction: Chagas disease (CD) remains a serious public health problem